Biomarker may affect chemo resistance in patients with advanced ovarian cancer
the ONA take:
miR-506, a non-coding RNA molecule that helps to control gene expression, may play a role in chemotherapy resistance in patients with ovarian cancer, according to a recent study published in the Journal of the National Cancer Institute.
Wei Zhang, PhD, of the MD Anderson Cancer Center and fellow researchers looked at patient data from The Cancer Genome Atlas and other independent clinical populations. In previous studies, they noted that the miR-506 molecule had the potential to sensitize cancer cells to chemotherapy.
In the present study, they found that response to chemotherapy drugs such as cisplatin and olaparib in epithelial ovarian cancer was significantly improved when miR-506 was added to the treatment.
“miR-506 was associated with better response to therapy and longer progression-free and overall survival,” Dr. Zhang said.
Previous studies found that the molecule was a potent inhibitor of epithelial-to-mesenchymal transition, which is associated with chemoresistance.
“This study provides further insight into this molecule’s role in augmenting chemotherapy responses by directly affecting the DNA repair process used by cancer cells to counter DNA damages caused by chemotherapy,” Dr. Zhang said.
miR-506 may play a role in chemotherapy resistance in patients with ovarian cancer.
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Obesity, Male Gender May Improve Survival Outcomes with Targeted and Immunotherapy in Melanoma
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Apalutamide Prolongs Time to Metastasis in Castration-resistant Prostate Cancer
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
- Zinc Sulfate Improves Chemotherapy-Induced Mucositis Outcomes in Leukemia
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Travel Distance to Prostate Cancer Treatment Influences Treatment Choice
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|